Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) is seeing a large increase in short interest

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP – Get Free Report ) received a significant increase in short interest in July. As of July 31st, there was short interest totaling 158,300 shares, an increase of 38.7% from July 15th’s total of 114,100 shares. Based on an average trading volume of 494,900 shares, the short interest rate is currently 0.3 days. Currently, 0.6% of the company’s shares are short sold.

Analysts set new price targets

Separately, LADENBURG THALM/SH SH lowered Coeptis Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, June 18th.

Read our latest research report on COEP

Institutional Trading of Coeptis Therapeutics

An institutional investor recently lifted its position in shares of Coeptis Therapeutics. Armistice Capital LLC grew its position in Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP – Free Report) by 59.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,520,000 shares of the company’s stock after buying an additional 1,308,000 shares during the quarter. Armistice Capital LLC owned 10.32% of Coeptis Therapeutics worth $2,759,000 at the end of the most recent reporting period. Institutional investors own 13.88% of the company’s shares.

Coeptis Therapeutics Stock Performance

COEP opened at $0.20 on Friday. The company’s 50-day moving average price is $0.27 and its two-hundred-day moving average price is $0.35. Coeptis Therapeutics has a 1 year low of $0.17 and a 1 year high of $1.38. The company has a market cap of $7.49 million, a price-to-earnings ratio of -0.38 and a beta of -0.90. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.60, and a quick ratio of 1.60.

Coeptis Therapeutics Company Profile

(Get a free report)

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for cancer patients. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia and acute myeloid leukemia; SNAP-CAR, a CAR T-cell therapy platform co-administered with labeled, tumor-specific antibodies to potentially target various tumor types, including hematologic malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze whether cancer patients might be suitable candidates for anti-CD38 mAb therapy.

See Also

Get news and reviews for Coeptis Therapeutics daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Coeptis Therapeutics and related companies with MarketBeat.com ‘s FREE daily email newsletter.